Voriconazole-resistant disseminated Paecilomyces variotii infection in a neutropenic patient with leukaemia on voriconazole prophylaxis.
Paecilomyces variotii, an emerging hyalohyphomycetes, has been reported to be susceptible in vitro to voriconazole. We describe a case of disseminated P. variotii infection in a neutropenic child with relapsed leukaemia who was on voriconazole prophylaxis. The P. variotii isolate was resistant to voriconazole in vitro. The patient responded to liposomal amphotericin B.
Chamilos
Georgios
G
Department of Infectious Diseases, Infection Control and Employee Health, Unit 402, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Kontoyiannis
Dimitrios P
DP
D000293:Adolescent; D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003881:Dermatomycoses / Q000188:drug therapy / Q000382:microbiology; D025141:Drug Resistance, Fungal; D016469:Fungemia / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008826:Microbial Sensitivity Tests; D009181:Mycoses / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000517:prevention & control; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy; D010143:Paecilomyces / Q000187:drug effects* / Q000302:isolation & purification; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D011859:Radiography; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D065819:Voriconazole